Yatharth Hospital Posts 46% Revenue Surge, New Hospitals Drive Growth

HEALTHCAREBIOTECH
Whalesbook Logo
Author Vihaan Mehta | Published at:
Yatharth Hospital Posts 46% Revenue Surge, New Hospitals Drive Growth
Overview

Yatharth Hospital and Trauma Care Services Ltd reported a strong Q3 FY26, with operating revenue soaring 46% year-over-year to Rs 3,205 million. Profit After Tax (PAT) climbed 41% to Rs 431 million, driven by the rapid scaling of newly operationalized hospitals in New Delhi and Faridabad. Despite strong top-line growth and a 35% YoY increase in EBITDA to Rs 742 million, EBITDA margins saw a slight contraction of 189 basis points to 23.2% due to the initial ramp-up phase of new facilities. The company remains confident in its growth trajectory.

Yatharth Hospital: New Facilities Power Robust Q3 FY26 Growth, Margin Watch Continues

Yatharth Hospital and Trauma Care Services Ltd has unveiled its Q3 FY26 financial results, demonstrating significant top-line expansion fueled by its strategic hospital network growth. The company posted a record operating revenue of ₹3,205 million for the quarter, a substantial 46% increase year-over-year from ₹2,192 million in Q3 FY25. This impressive revenue surge was primarily driven by the successful ramp-up of its newly operationalized hospitals in New Delhi and Faridabad Sec-20.

Profit After Tax (PAT) mirrored this strong performance, growing by 41% YoY to ₹431 million, up from ₹305 million in the corresponding prior-year period. For the nine months ended FY26 (9MFY26), revenue reached ₹8,577 million, up 32% YoY, with PAT increasing by 38% YoY to ₹1,264 million.

EBITDA for the quarter stood at ₹742 million, a robust 35% increase YoY. However, a key point of analysis is the contraction in EBITDA margins, which decreased by 189 basis points YoY to 23.2% in Q3 FY26 from 25.1% in Q3 FY25. Management attributes this margin dip to the initial operational ramp-up phase of the new facilities, a common occurrence that typically resolves as these units mature. The company highlighted an Adjusted EBITDA Margin of 29.2%, excluding these initial ramp-up losses, signaling underlying profitability resilience.

Income Statement Drivers

The newly established hospitals in New Delhi and Faridabad Sec-20 were significant contributors, generating ₹279 million in revenue, accounting for 9% of the Group's total revenue in their first full quarter of operations. A strategic focus on improving the payer mix was evident, as these facilities generated 100% of their revenue from cash and TPA patients, with 0% business from government schemes. This aligns with the company's strategy to enhance profitability through a more favorable revenue stream. Existing hospitals also showcased solid performance, reporting 33% YoY growth.

The Average Revenue Per Operating Bed (ARPOB) saw a healthy 10% YoY increase to ₹33,744, reflecting improved service utilization and pricing power.

Financial Deep Dive

The Numbers:

  • Revenue (Q3 FY26): ₹3,205 million (+46% YoY)

  • PAT (Q3 FY26): ₹431 million (+41% YoY)

  • EBITDA (Q3 FY26): ₹742 million (+35% YoY)

  • EBITDA Margin (Q3 FY26): 23.2% (-189 bps YoY)

The Quality:
While revenue and profit figures are strong, the EBITDA margin compression warrants attention. However, the provided Adjusted EBITDA Margin of 29.2% suggests that underlying operational efficiency is strong once new facilities stabilize. The focus on cash and TPA patients in new units is a positive step towards a healthier payer mix.

The Grill:
While the provided text does not detail an analyst 'grill', the margin contraction is a key point that investors will likely scrutinize further on the upcoming earnings call. Management's proactive explanation and the provision of an adjusted margin figure aim to preempt concerns. The rapid achievement of Monthly Revenue Run Rate (MRR) targets for the New Delhi (₹5 crore within 4 months) and Faridabad Sec-20 (₹7-8 crore within 3 months) facilities indicates strong operational execution.

Balance Sheet & Cash Flow:
Specific details regarding the company's balance sheet (assets, liabilities, net debt) and cash flow metrics (operating cash flow, CapEx, free cash flow) were not provided in this announcement.

Risks & Outlook

Specific Risks:
The primary risk remains the pace at which the new facilities (New Delhi, Faridabad Sec-20) achieve optimal operational efficiency and margin recovery, moving closer to the group's historical averages. Execution risks associated with integrating the recently acquired Agra facility (effective February 2026) will also need careful monitoring.

The Forward View:
Management expresses significant optimism, projecting sustained accelerated growth. Key focus areas for investors to watch in the coming quarters will be:

  • Margin Recovery: The trajectory of EBITDA margins as new hospitals mature.

  • Integration Success: The performance and profitability of the Agra facility post-integration.

  • ARPOB Growth: Continued increase in ARPOB across the network.

  • Payer Mix: Sustaining the focus on cash and TPA patients in newer units.

The company's strategy of consolidating new assets, onboarding star doctors, and maintaining clinical excellence forms the bedrock of its long-term value creation strategy.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.